Shares of CSL Limited (OTCMKTS:CSLLY - Get Free Report) reached a new 52-week low during mid-day trading on Monday . The stock traded as low as $71.95 and last traded at $73.35, with a volume of 210356 shares trading hands. The stock had previously closed at $74.44.
Analyst Ratings Changes
Separately, The Goldman Sachs Group raised shares of CSL to a "strong-buy" rating in a research note on Thursday, January 16th.
View Our Latest Stock Report on CSLLY
CSL Stock Performance
The business has a 50-day simple moving average of $80.04 and a 200 day simple moving average of $87.60. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.18 and a quick ratio of 0.97.
CSL Company Profile
(
Get Free Report)
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.
Featured Stories
Before you consider CSL, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CSL wasn't on the list.
While CSL currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
